Market Overview

Saudi Arabia biosimilar market size reached USD 664.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,990.5 Million by 2034, exhibiting a growth rate (CAGR) of 12.97% during 2026-2034. The biosimilar sector in Saudi Arabia is rapidly expanding, driven by strong regulatory support from the health authority, healthcare transformation efforts, and increasing adoption for treating chronic conditions. With numerous approved alternatives available, it enhances affordability and access to advanced biologic therapies while sustaining quality and safety standards.

How AI is Reshaping the Future of saudi arabia biosimilar market:

• AI speeds up drug discovery and development for biosimilars, letting companies simulate processes and cut costs while aligning with Vision 2030's push for local biomanufacturing and greater self-sufficiency in biologics production.

• The SFDA leverages AI to streamline approval processes for medicines including biosimilars, making evaluations faster and more efficient so innovative treatments reach patients quicker in the Kingdom.

• Companies like Sandoz use AI-driven platforms to expand their biosimilar pipelines and boost innovation, supporting Saudi Arabia's goal of over 60% biosimilar penetration to improve affordability and access.

• AI enables precision medicine approaches in biosimilars by analyzing patient data and genetics, helping tailor treatments for common conditions like diabetes and cancer prevalent in Saudi Arabia.

• With the biosimilar market valued around USD 664 million recently, AI supports localization efforts through advanced analytics, helping reduce healthcare costs and build a stronger domestic biotech hub under national strategies.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-biosimilar-market/requestsample

Market Growth Factors

The Saudi Arabia biosimilars market is witnessing robust expansion as healthcare authorities and providers increasingly embrace these alternatives to originator biologics. A key trend involves the progressive adoption across therapeutic areas such as oncology, autoimmune diseases, and diabetes management, supported by growing confidence in their comparability to reference products. Regulatory advancements by the Saudi Food and Drug Authority (SFDA), including streamlined approval pathways and waivers for certain comparative studies when supported by strong analytical and pharmacokinetic data, are facilitating faster market entry. This environment encourages greater penetration in both public and private sectors, aligning with broader efforts to modernize pharmaceutical access and promote evidence-based utilization among physicians and patients.

Government initiatives under Vision 2030 serve as a primary driver, emphasizing localization of biomanufacturing and self-sufficiency in producing biologics and biosimilars to reduce reliance on imports. The National Biotechnology Strategy specifically targets establishing advanced platforms for biosimilar development, fostering domestic production capabilities and export potential while creating skilled employment opportunities. These policies integrate with health transformation programs that prioritize sustainable spending and enhanced patient access to advanced therapies, thereby stimulating investment from local and international players and accelerating the shift toward biosimilars as a strategic component of the pharmaceutical ecosystem.

Rising prevalence of chronic conditions, coupled with escalating demands on the healthcare budget, propels the shift toward cost-effective treatment options without compromising quality or efficacy. Biosimilars offer a practical solution to expand access to previously expensive biologic therapies, particularly in specialized care settings. Increasing acceptance among healthcare professionals, bolstered by real-world evidence and educational efforts, further supports broader integration. Collaborative frameworks between regulators, payers, and industry stakeholders continue to refine procurement and reimbursement mechanisms, ensuring biosimilars contribute effectively to improved affordability and overall system efficiency in the Kingdom.

Market Segmentation

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Manufacturing Type Insights:

• In-House Manufacturing
• Contract Manufacturing

Regional Insights:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent Developement & News

• February 2026: Bio-Thera Solutions and Avalon Pharma signed a commercialization and license agreement for BAT3306, a proposed biosimilar to pembrolizumab (Keytruda), covering Saudi Arabia and the MENA region. Avalon handles regulatory approvals and commercialization, while Bio-Thera manages development, manufacturing, and supply, aiming to improve access to immuno-oncology treatments.
• October 2025: MS Pharma's biologics manufacturing facility in Riyadh obtained GMP certification from the SFDA following a June inspection. This strengthens local production capabilities for biosimilars and supports Vision 2030 goals for pharmaceutical localization in the GCC and MENA markets.
• January 2026: The SFDA updated its biosimilars regulatory framework during a workshop, removing the default requirement for comparative clinical efficacy studies in approvals. This streamlines the process, reduces development burdens, and accelerates market entry for biosimilars while maintaining quality and comparability standards.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302